ASCO

ASCO Endorses Active Surveillance for Prostate Cancer
The American Society of Clinical Oncology (ASCO) now recommends active surveillance instead of immediate treatment for most men with low-risk prostate cancer. The recommendation comes by way of an endorsement of guidelines from Cancer Care ... [...]
4
Like
Save
ASCO GU 2016 Large Study Reveals Significant Glucocorticoid Use in Both …
San Francisco, CA USA (UroToday.com) In an analysis of a very large database to elucidate the prevalence of glucocorticoid use among both treated and untreated prostate cancer patients, 70% of patients who received chemotherapy and 88% of patients ... [...]
3
Like
Save
ASCO GU 2016 More CNS Events With Enzalutamide Vs. Bicalutamide Treatment of …
San Francisco, CA USA (UroToday.com) Among men with metastatic castration resistant prostate cancer (mCRPC) who were initiated on enzalutamide or bicalutamide treatment, more central nervous system (CNS) events occurred with enzalutamide, even ... [...]
4
Like
Save
ASCO GU 2016 Evaluating abiraterone responses in African Americans with …
In total 103 men with metastatic castration-resistant prostate cancer (mCRPC) were treated with abiraterone during the period of the study, including 24 African American men and 79 Caucasian men. Men had similar baseline age (61.8 years for African ... [...]
1
Like
Save
ASCO GU 2016 Molecular Risk Stratification in Localized Prostate Cancer …
San Francisco, CA USA (UroToday.com) Dr. Robert Bristow of the Princess Margaret Cancer Centre in Toronto presented data from work by the International Cancer Genome Consortium that attempted to characterize patients by molecular patterns to allow ... [...]
7
Like
Save